Clinical Trials Using Bevacizumab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Bevacizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 74
1 2 3 Next >

  • Combination Chemotherapy, Bevacizumab, and / or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

    This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and / or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
    Location: 150 locations

  • The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

    This is a multicenter, randomized, open-label phase 2 / 3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD
    Location: 22 locations

  • A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
    Location: 28 locations

  • A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

    This is an international multi-center, prospective, open-label, randomized phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
    Location: 22 locations

  • Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and / or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This randomized phase II / III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and / or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. block tumor growth Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 20 locations

  • Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients with Recurrent Glioblastoma

    This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 10 locations

  • Capecitabine and Bevacizumab with or without Atezolizumab in Treating Patients with Refractory Metastatic Colorectal Cancer

    This randomized phase II trial studies how well atezolizumab and capecitabine with or without bevacizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places. Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with capecitabine and bevacizumab may be a better way in treating colorectal cancer.
    Location: 12 locations

  • Genetic Testing in Determining Irinotecan Hydrochloride Dose in Patients with Metastatic Colorectal Cancer Receiving FOLFIRI and Bevacizumab

    This phase II trial studies how well genetic testing works in determining irinotecan hydrochloride dose in patients with colorectal cancer that has spread to other areas of the body, who are receiving leucovorin calcium, fluorouracil, and irinotecan hydrochloride (FOLFIRI) and bevacizumab. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving monoclonal antibody therapy with chemotherapy may kill more tumor cells. Genetic testing may help doctors determine how the body breaks down and removes irinotecan hydrochloride. Using genetic testing to determine the dose of irinotecan hydrochloride may be more effective and safer than standard dosing.
    Location: 9 locations

  • A Phase 1 / 1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors

    This is a Phase 1 / 1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 in subjects with advanced solid tumors.
    Location: 9 locations

  • Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

    In this study, investigators will conduct a phase I / II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies.
    Location: 7 locations

  • Osimertinib and Bevacizumab in Treating Patients with Metastatic EGFR-Mutant Non-small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of osimertinib when given together with bevacizumab and to see how well they work in treating patients with non-small cell lung cancer that has an epidermal growth factor receptor (EGFR) mutation and has spread from where it started to other places in the body. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Giving osimertinib and bevacizumab may work better in treating patients with non-small cell lung cancer with an EGFR mutation.
    Location: 6 locations

  • A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and / or Other Treatments in Participants With Solid Tumors

    This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.
    Location: 10 locations

  • Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

    This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields or TTF Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.
    Location: 6 locations

  • Atezolizumab and Bevacizumab in Treating Patients with Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with kidney cancer that is no longer responding to treatment or has spread to other parts of the body. Monoclonal antibodies, such as atezolizumab and bevacizumab may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

    The purpose of the study is to determine the overall response rate of single agent TRC105 and the combination of TRC105 and bevacizumab in patients with refractory GTN (including choriocarcinoma, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT)). Up to 30 patients will be treated.
    Location: 5 locations

  • Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer

    This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: IMGN853 administered with bevacizumab, IMGN853 administered with carboplatin, IMGN853 administered with pegylated liposomal doxorubicin, IMGN853 administered with pembrolizumab, or IMGN853 administered with bevacizumab+carboplatin
    Location: 6 locations

  • Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma

    This phase II trial studies how well carboplatin and bevacizumab work in treating patients with ependymoma that has come back. Drugs used in chemotherapy, such as carboplatin, interfere with the growth of tumor cells by stopping cell division, which may cause the cells to die. Monoclonal antibodies, such as bevacizumab, may prevent or slow down the growth of tumor cells by blocking the growth of blood vessels. Giving carboplatin and bevacizumab may be an effective treatment for ependymoma.
    Location: 4 locations

  • A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

    This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.
    Location: 4 locations

  • Pulse Reduced Dose-Rate Radiation Therapy and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Anaplastic Glioma Previously Treated with Radiation Therapy, Temozolomide, and / or Bevacizumab

    This phase II trial studies how well pulse reduced dose-rate (PRDR) radiation therapy and bevacizumab work in treating patients with glioblastoma or anaplastic glioma that has come back after treatment with radiation therapy, temozolomide, and / or bevacizumab. PRDR radiation therapy uses high energy x-rays to kill tumor cells but at a much slower rate and may be effective in inducing tumor regression. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. Giving PRDR radiation therapy and bevacizumab may be effective in treating patients with recurrent glioblastoma or anaplastic glioma.
    Location: 3 locations

  • Brentuximab Vedotin and Bevacizumab in Treating Patients with Recurrent and Refractory CD-30 Positive Germ Cell Tumors

    This phase II trial studies how well brentuximab vedotin and bevacizumab work in treating patients with CD-30 positive germ cell tumors that has come back and does not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin and bevacizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

    This is an open-label, multicenter, single-arm, two-stage, Phase Ib study designed to assess the safety, tolerability, and pharmacokinetics of oral cobimetinib with intravenous (IV) atezolizumab and bevacizumab in participants with metastatic colorectal cancer (mCRC) who have received and progressed on at least one prior line of therapy that contained a fluoropyrimidine and oxaliplatin or irinotecan. There are two stages in this study: Stage 1 (safety run-in phase) and Stage 2 (dose expansion phase with two cohorts, an expansion cohort and a biopsy cohort).
    Location: 2 locations

  • TORC1 / 2 Inhibitor MLN0128 and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Advanced Solid Tumors

    This phase I trial studies the side effects and best dose of raptor / rictor-mammalian target of rapamycin (mTOR) (TORC1 / 2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type of brain tumor, or a solid tumor that has spread and not responded to standard treatment. TORC1 / 2 inhibitor MLN0128 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the progression of tumors by blocking the growth of new blood vessels necessary for tumor growth.
    Location: 3 locations

  • Carbon C 11 Temozolomide, PET, and MRI in Studying Tumor Blood Vessels in Patients with Recurrent Glioblastoma Receiving Bevacizumab and Temozolomide

    This pilot clinical trial studies carbon C 11 temozolomide, positron emission tomography (PET), and magnetic resonance imaging (MRI) in studying tumor blood vessels in patients with brain tumors that have come back and are receiving bevacizumab and temozolomide. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab works by blocking signals of a specific protein called vascular endothelial growth factor (VEGF) therefore slowing the growth of cancer. Since anti-VEGF agents also affect normal blood vessels in the brain, they may inhibit the way temozolomide is delivered to the tumor. Using a radioactive substance, such as carbon C 11 temozolomide, PET, and MRI may allow doctors to evaluate the changes in tumor blood flow, blood volume, and how receptive blood vessels are while also measuring how much temozolomide is in the brain.
    Location: 2 locations

  • Electric Field Therapy and Bevacizumab in Treating Patients with Recurrent Glioblastoma

    This phase II trial studies how well electric field therapy and bevacizumab work in treating patients with glioblastoma that has come back. Electric field therapy uses medium frequency electric current to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving electric field therapy and bevacizumab may work better in treating patients with glioblastoma.
    Location: 3 locations

  • Risk Adapted Focal Proton Beam Radiation and / or Surgery in Participants with Low, Intermediate, and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    This phase II trial studies how well chemotherapy, surgery, and radiation therapy work in treating patients with newly diagnosed rhabdomyosarcoma that has spread to other parts of the body. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.
    Location: 3 locations


1 2 3 Next >